Oligometastatic prostate cancer (OMPCa) is emerging as a transitional disease state between localized and polymetastatic disease. This review will assess the current knowledge of castrate-sensitive OMPCa.
A review of the current literature was performed to summarize the definition and classification of OMPCa, assess the diagnostic methods and imaging modalities utilized, and to review the treatment options and outcomes. We further identify gaps in knowledge and areas for future research.
Currently there is no unified definition of OMPCa. National guidelines mostly recommend systemic therapies without distinguishing oligometastatic and polymetastatic disease. Next generation imaging is more sensitive than conventional imaging and has led to early detection of metastases at initial diagnosis or recurrence. While mostly retrospective in nature, recent studies suggest that treatment (surgical or radiation) of the primary tumor and/or metastatic sites might delay initiation of androgen deprivation therapy while increasing survival in selected patients.
Prospective data are required to better assess the incremental improvement in survival and quality of life achieved with various treatment strategies in patients with OMPCa.
Prostate cancer and prostatic diseases. 2023 Jul 08 [Epub ahead of print]
Rand N Wilcox Vanden Berg, Thomas Zilli, Vérane Achard, Tanya Dorff, Michael Abern
Department of Urology, Duke University, Durham, NC, USA., Radiation Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland., Faculty of Medicine, University of Geneva, Geneva, Switzerland., City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Department of Urology, Duke University, Durham, NC, USA. .